Neocutis products developed a technology platform based on an in-depth understanding of scarless wound healing. This platform has multiple applications in wound healing, dermatology and skin care, helping to even skin tones and provide noticeable anti-aging benefits.
Neocutis began with a simple observation: prenatal surgery can be done without scar formation after birth. The “Laboratoire de Médecine Foetale” at the Medical School of the University Hospital of Lausanne has worked extensively with fetal cells since 1995 and resulted in several patent applications. In July 2004, a group of financial investors led by Venture Incubator closed a financial deal. This financing enabled Neocutis skincare to launch its first product in the US market, "Neocutis Bio-restorative Skin Cream"; a cosmeceutical sold only through physicians.
